Skip to main content
NCBI home page
NPJ Digital Medicine logoLink to NPJ Digital Medicine
. 2024 Aug 26;7:228. doi: 10.1038/s41746-024-01220-7

Digital twins in dermatology, current status, and the road ahead

Hossein Akbarialiabad 1, Amirmohammad Pasdar 2, Dédée F Murrell 1,3,✉
PMCID: PMC11347578  PMID: 39187568

Abstract

Digital twins, innovative virtual models synthesizing real-time biological, environmental, and lifestyle data, herald a new era in personalized medicine, particularly dermatology. These models, integrating medical-purpose Internet of Things (IoT) devices, deep and digital phenotyping, and advanced artificial intelligence (AI), offer unprecedented precision in simulating real-world physical conditions and health outcomes. Originating in aerospace and manufacturing for system behavior prediction, their application in healthcare signifies a paradigm shift towards patient-specific care pathways. In dermatology, digital twins promise enhanced diagnostic accuracy, optimized treatment plans, and improved patient monitoring by accommodating the unique complexities of skin conditions. However, a comprehensive review across PubMed, Embase, Web of Science, Cochrane, and Scopus until February 5th, 2024, underscores a significant research gap; no direct studies on digital twins’ application in dermatology is identified. This gap signals challenges, including the intricate nature of skin diseases, ethical and privacy concerns, and the necessity for specialized algorithms. Overcoming these barriers through interdisciplinary efforts and focused research is essential for realizing digital twins’ potential in dermatology. This study advocates for a proactive exploration of digital twins, emphasizing the need for a tailored approach to dermatological care that is as personalized as the patients themselves.

Subject terms: Medical research, Clinical trial design

Introduction

Health digital twins represent a pioneering leap in personalized medicine, embodying virtual replicas of individual patient health that merge comprehensive biological, environmental, and lifestyle data. These sophisticated models simulate real-world physical conditions within a digital framework, enabling physicians to predict health outcomes, optimize treatment plans, and monitor disease progression in real-time1,2. Initially conceptualized for aerospace and manufacturing to predict system behaviors and maintenance needs, the application of digital twin technology in healthcare marks a significant evolution, offering unprecedented insights into patient-specific care pathways2–5. In medicine, digital twin technology has emerged as a frontier in personalizing patient care, with applications involving cardiology, neurology, surgery, and oncology, demonstrating its ability to enhance diagnostic accuracy, optimize treatment plans, and improve patient outcomes6–9.

Digital twins for health are achieved through the seamless integration of medical-purpose Internet of Things (IoT) devices10–13, deep phenotyping14–16, digital phenotyping17–19,and artificial intelligence (AI) for disease progression simulation and treatment evaluation20,21. IoT’s role is pivotal, providing continuous health data, while deep phenotyping uncovers genetic and molecular insights crucial for understanding individual health risks and conditions. Digital phenotyping further adds to this personalized approach by including environmental and lifestyle factors, enriching the patient’s health profile for more holistic care strategies. AI, the core analytical engine, leverages this data to offer predictive insights and personalized treatment pathways. Additionally, integrating cyber-physical systems6,22 ensures that digital twins can adapt in real-time, enhancing the precision and effectiveness of dermatological care.

The field of dermatology is experiencing a remarkable evolution, driven by the digital revolution that has begun to permeate medical science23,24. In recent years, the burgeoning interest in digital dermatology has been marked by the emergence of multiple AI applications, each promising to enhance diagnostic accuracy, treatment personalization, and patient monitoring20. Among the interdisciplinary innovations garnering attention within the dermatology community, the digital twin concept stands out as a promising frontier. This technology, by merging deep phenotyping14 with digital phenotyping17,18 and the IoT25, offers a comprehensive and dynamic representation of the patient’s health and skin condition, setting the stage for a new era of personalized dermatological care7. This approach is particularly pertinent given the skin’s status as the body’s largest organ26, subject to various conditions influenced by internal and external factors (Fig. 1).

Fig. 1. Elements of digital twins in dermatology.

Fig. 1

Open in a new tab

This figure illustrates the various components and technologies involved in the concept of digital twins in dermatology. It showcases the integration of IoT devices, deep phenotyping, digital phenotyping, and artificial intelligence. The visual representation emphasizes the combination of real-time biological, environmental, and lifestyle data to create sophisticated virtual models that simulate real-world conditions and predict health outcomes. The diagram highlights the potential for personalized care, enhanced diagnostic accuracy, and optimized treatment plans in dermatology, illustrating the interdisciplinary nature of this innovative technology.

Although the use of digital twins for health has increasingly become popular9, a potential gap is identified in integrating this concept into dermatology. Despite searching five major digital libraries, PubMed, Scopus, Web of Science, Cochrane Library, and Embase, with a comprehensive set of keywords and lack of any language restrictions, as of 05 February 2024, we found no eligible relevant study after evaluating the included 157 papers (Fig. 2, and Supplementary file). Our findings revealed a significant gap in research focused on the application of digital twins in dermatology. This gap indicates that while digital twins have been successful in other areas of medicine, their potential in dermatology remains largely untapped.

Fig. 2. PRISMA flow diagram for study selection.

Fig. 2

Open in a new tab

The PRISMA flow diagram outlines the selection process for the studies included in this systematic review. Starting with 157 records identified from five major databases (Scopus, WOS, PubMed, Cochrane, Embase), the process involved removing duplicates, screening for relevance, and assessing full-text articles for eligibility. Ultimately, no studies met the criteria for inclusion, highlighting a significant research gap in the application of digital twins in dermatology. The diagram visually represents the filtering steps from identification to final inclusion, demonstrating the thorough methodology employed in this scoping review.

Digital twins in dermatology from clinical perspectives

The concept of digital twins in dermatology comes with two significant potentials from the perspective of clinical visits and trials. The former involves patients seeking medical care for different skin-related concerns, and through a thorough evaluation, dermatologists offer treatment recommendations and monitor their skin health over time. The latter is about research studies focused on developing and evaluating new treatments or procedures aimed at the skin condition through investigating safety, efficacy, and potential side effects. These perspectives can be significantly facilitated through the integration of digital twins, elaborated in the following.

Potential in regular clinical visits

Imagine a dermatologist facing a patient with severe psoriasis, aiming to initiate biologic therapy to maximize efficacy while minimizing the risk of failure. Here, digital twins play a crucial role as a cutting-edge tool combining genetic data (deep phenotyping) with real-time environmental and lifestyle data (digital phenotyping) from IoT devices. In such a scenario, developing an appropriate physical-digital interface (cyber-physical systems) and using the analytical power of AI with such information can contribute. These comprehensive digital models allow dermatologists to simulate and evaluate the effects of various treatment options on the patient’s skin condition, potentially relevant mutations27, and associated comorbidities such as arthritis, fatty liver, hypertension, and insulin resistance.

Such models could extend beyond superficial analysis, offering insights into inflammation and other key biomarkers, as well as even skin microbiome, which is crucial for understanding the intricacies of the disease. The computational capability of digital twins to simulate the patient’s response to different therapies enables an accurate prediction of treatment outcomes. Consequently, the digital twin acts as a virtual testing environment, facilitating the selection of the most suitable biologic therapy that promises significant symptom relief, minimal side effects, and durable disease management, all tailored to the patient’s unique dermatological needs.

Potential in clinical trials

In the context of clinical trials, the use of digital twins offers a novel approach to addressing ethical concerns associated with control arms, where patients might otherwise be deprived of effective treatments28–31. Traditional clinical trials necessitate the inclusion of a control group, often receiving a placebo or standard treatment, against which the efficacy of a new therapeutic intervention is measured. However, this model raises ethical dilemmas, especially in trials for conditions with severe morbidity or where effective treatments are already available. This issue is more highlighted with diseases like epidermolysis bullosa, in which randomized control trials (RCTs) may predispose the untreated control group on a placebo to a risk of highly aggressive squamous cell carcinoma.

Digital twins can revolutionize this aspect by providing a virtual control arm. With digital twins in place, a corresponding digital twin could be created for each participant in the treatment group of a clinical trial. When considering treatment options, the digital twin allows researchers to simulate the outcomes of various interventions, including the new treatment under investigation and the existing standard of care or placebo effect. In essence, the digital twin undergoes the “control” treatment in a virtual environment, eliminating the need to withhold potentially more effective treatments from any real patient. This method not only upholds the ethical principle of providing the best available care but also maintains the scientific rigor of clinical trials by allowing for a comparison between new interventions and the current standard without compromising patient well-being.

Moreover, as the trial progresses, real-time data from patients undergoing the actual treatment can be fed back into the digital twins, allowing for continuous refinement of the models and enabling adjustments to treatment protocols based on emerging data. This dynamic process enhances the predictive accuracy of the digital twins, making them even more valuable as virtual controls.

It is apparent that this innovative approach could be particularly transformative in dermatology, where the visual and symptomatic nature of skin conditions often requires immediate and effective treatment interventions. By integrating digital twins as virtual control arms in clinical trials, dermatology can advance its research methodology, ensuring patients receive the most effective treatments while generating robust data on new therapies’ efficacy and safety.

Precision medicine in dermatology

Medical treatment and healthcare can significantly benefit from precision medicine (i.e., personalized medicine). It is an innovative approach that considers genetics, environment, and lifestyle differences for enhanced disease decision-making. Precision medicine in dermatology particularly customizes medical treatments for skin conditions based on individual patients’ characteristics. This treatment customization, however, is more complex than a simplistic binary approach, necessitating a progressive evolution toward more sophisticated models, benefiting from advancements in image processing with convoluted neural networks32–34 and multi-functioning skin biosensors35–37. Furthermore, innovative approaches from closely-related domains, their integration, and adaptability are valuable, e.g., analyzing skin temperature through a computer-simulated model through complex thermoregulation intended initially for energy and architectural research38. This model can shed new light on dermatologic applications if utilized correctly.

Additionally, novelties from domains other than medicine can be inspirational. Atashipour et al.39, from the mechanical engineering domain, have introduced a novel approach for predicting the material properties of soft tissues, including skin, by analyzing vibration data. They employed measured full-field displacements in a reverse-engineering algorithm to update models and create a digital twin of desired tissues, including skin, to examine its response to vibrations. Such methodologies could be pivotal in clinical dermatology for predicting the mechanical properties of multi-layered skin (including skin thickness) through resonance frequencies and comprehensive imaging techniques.

Issues and future research direction

Implementing digital twins in healthcare raises significant data privacy and ethical issues. Dermatology, which often involves sensitive patient data related to skin conditions that can affect individuals’ appearance and psychological well-being, may face heightened concerns regarding such data’s secure and ethical use. This requires establishing clear guidelines and protocols for data privacy, consent, and security specific to using digital twins in dermatology as well as engaging patients in the conversation around data use.

Creating and maintaining digital twins demands substantial computational power and technical expertise. The field of dermatology may not yet have the infrastructure or the workforce adequately trained in these high-tech tools to implement digital twin technology effectively. This can become complicated further due to the existence of complex dermatological data. It is unlike conditions such as hypertension or diabetes, where disease parameters are relatively straightforward to quantify. Therefore, dermatological conditions involve complex visual data that require advanced image processing and pattern recognition technologies for effective digital twin modeling.

Digital twins can utilize electronic health records and other existing health data sources to enrich digital twins with real-world clinical data, enhancing their accuracy and utility in dermatological practice. This data integration should be accompanied by prioritizing, developing, and improving algorithms capable of processing and analyzing extensive dermatological data (e.g., images or telemetry data from medical-purpose IoT devices). However, advanced data pipelines and algorithms may incur costs and bring resource allocation challenges for the development and maintenance of digital twins within healthcare budgets. Conducting comprehensive cost-benefit analyses and exploring scalable, cost-effective technological solutions, such as “cloud computing,” “edge computing,” or “edge AI,” are vital steps to justify and manage the investment in digital twin technologies.

Developing digital twins not only requires close collaboration between clinicians, computer scientists, data analysts, and other experts, but also the interoperability challenges between disparate healthcare systems and the digital twin platform should be addressed. The seamless integration of diverse health data sources is crucial for accurately modeling digital twins. Thus, adopting universal healthcare data standards and developing adaptable middleware solutions can facilitate this integration, ensuring that digital twins can be effectively utilized across different healthcare settings. Moreover, the siloed nature of research and clinical practice may impede the interdisciplinary collaboration necessary to successfully integrate digital twins in dermatology. Hence, it necessitates interdisciplinary partnerships that encourage collaboration between dermatologists, computer scientists, data analysts, and patients to co-develop digital twin models that are clinically relevant and patient centric. It even requires developing specialized training programs for dermatologists and healthcare professionals on digital dermatology, including digital twin technology, focusing on its potential applications, benefits, and ethical considerations in dermatology.

Moreover, while rapidly evolving, digital twin technology is still considered nascent in many healthcare areas, including dermatology. Its application has been more prominent in sectors with a more extended digitization and data integration history, such as manufacturing and aerospace.There may also have been a historical bias towards investing in digital health innovations in fields with broader public health impacts, such as cardiology or neurology. This could inadvertently lead to dermatology being underrepresented in digital health research and development initiatives. Therefore, pilot projects can explore the feasibility and effectiveness of digital twins in managing specific dermatological conditions, such as dermatologic orphan diseases with limited populations for RCT.

Another critical issue is ensuring equitable access to digital twin technologies. There is a risk that such advanced treatments could be disproportionately available to those in technologically advanced or higher-income regions, exacerbating existing healthcare disparities. Addressing this requires innovative solutions, such as public-private partnerships to subsidize technology costs and utilizing widely accessible mobile technologies to democratize access to digital twin-based treatments40.

Conclusion

The use of digital twins in dermatology promises enhanced diagnostic accuracy, optimized treatment plans, and improved patient monitoring by accommodating the unique complexities of skin conditions. The identified gap in utilizing digital twins application emphasizes the need for research to address challenges, including the intricate nature of skin diseases, ethical and privacy concerns, and the necessity for specialized algorithms. Overcoming these barriers through interdisciplinary efforts and focused research is essential for realizing digital twins’ potential in dermatology, highlighting the need for a tailored approach to dermatological care as personalized as the patients themselves. Hence, dermatology can advance toward a future where personalized and predictive care is envisioned and realized through the power of digital twins.

Supplementary information

Supplemetary File (177.2KB, pdf)

Author contributions

H.A., A.P., and D.F.M. contributed to the conceptualization of this paper. H.A. made the initial draft. H.A., A.P., and D.F.M. participated in revising the manuscript and approved the completed version.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

The online version contains supplementary material available at 10.1038/s41746-024-01220-7.

References

  • 1.Lareyre, F., Adam, C., Carrier, M. & Raffort, J. Using digital twins for precision medicine in vascular surgery. Ann. Vasc. Surg.67, e577–e578 (2020). 10.1016/j.avsg.2020.04.042 [DOI] [PubMed] [Google Scholar]
  • 2.Erol, T., Mendi, A. F. & Doğan, D. In 2020 4th international symposium on multidisciplinary studies and innovative technologies (ISMSIT). 1–7 (IEEE, 2021).
  • 3.Barricelli, B. R., Casiraghi, E. & Fogli, D. A survey on digital twin: definitions, characteristics, applications, and design implications. IEEE Access7, 167653–167671 (2019). 10.1109/ACCESS.2019.2953499 [DOI] [Google Scholar]
  • 4.Kritzinger, W., Karner, M., Traar, G., Henjes, J. & Sihn, W. Digital twin in manufacturing: a categorical literature review and classification. Ifac-PapersOnline51, 1016–1022 (2018). 10.1016/j.ifacol.2018.08.474 [DOI] [Google Scholar]
  • 5.Corral-Acero, J. et al. The ‘Digital Twin’to enable the vision of precision cardiology. Eur. Heart J.41, 4556–4564 (2020). 10.1093/eurheartj/ehaa159 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Sun, T., He, X., Song, X., Shu, L. & Li, Z. The digital twin in medicine: a key to the future of healthcare?. Front. Med.9, 907066 (2022). 10.3389/fmed.2022.907066 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Kamel Boulos, M. N. & Zhang, P. Digital twins: from personalised medicine to precision public health. J. Personal. Med.11, 745 (2021). 10.3390/jpm11080745 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Coorey, G. et al. The health digital twin to tackle cardiovascular disease—a review of an emerging interdisciplinary field. NPJ Digit. Med.5, 126 (2022). 10.1038/s41746-022-00640-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Shamanna, P. et al. Retrospective study of glycemic variability, BMI, and blood pressure in diabetes patients in the digital twin precision treatment program. Sci. Rep.11, 14892 (2021). 10.1038/s41598-021-94339-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Ahmed, A., Rushworth, J. V., Hirst, N. A. & Millner, P. A. Biosensors for whole-cell bacterial detection. Clin. Microbiol. Rev.27, 631–646 (2014). 10.1128/CMR.00120-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Sánchez-Tirado, E. et al. Electrochemical (Bio) sensing devices for human-microbiome-related biomarkers. Sensors23, 837 (2023). 10.3390/s23020837 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Ngashangva, L. & Chattopadhyay, S. Biosensors for point-of-care testing and personalized monitoring of gastrointestinal microbiota. Front. Microbiol.14, 1114707 (2023). 10.3389/fmicb.2023.1114707 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Vadela, M. B., Karri, S. & Gundi, V. A. In Human Microbiome in Health, Disease, and Therapy 265–285 (Springer, 2023).
  • 14.Yurkovich, J. T., Tian, Q., Price, N. D. & Hood, L. A systems approach to clinical oncology uses deep phenotyping to deliver personalized care. Nat. Rev. Clin. Oncol.17, 183–194 (2020). 10.1038/s41571-019-0273-6 [DOI] [PubMed] [Google Scholar]
  • 15.Suzuki, Y. et al. Deep phenotyping of superficial Epidermolytic ichthyosis due to a recurrent mutation in KRT2. Int. J. Mol. Sci.23, 7791 (2022). 10.3390/ijms23147791 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Maintz, L. et al. Machine learning–based deep phenotyping of atopic dermatitis: severity-associated factors in adolescent and adult patients. JAMA Dermatol.157, 1414–1424 (2021). 10.1001/jamadermatol.2021.3668 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Onnela, J.-P. Opportunities and challenges in the collection and analysis of digital phenotyping data. Neuropsychopharmacology46, 45–54 (2021). 10.1038/s41386-020-0771-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Akbarialiabad, H. et al. Threats to global mental health from unregulated digital Phenotyping and Neuromarketing: recommendations for COVID-19 era and beyond. Front. Psychiatry12, 713987 (2021). 10.3389/fpsyt.2021.713987 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Shen, F. X. et al. Returning individual research results from digital phenotyping in psychiatry. Am. J. Bioeth.24, 69–90 (2024). 10.1080/15265161.2023.2180109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Jueng, J. et al. Using artificial intelligence to analyze publicly available social media posts to understand patient perspectives toward specific treatments of alopecia areata. JAAD Int.9, 102 (2022). 10.1016/j.jdin.2022.08.021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Akbarialiabad, H. & Murrell, D. A new dawn for orphan diseases in dermatology: the transformative potential of digital twins. J. Eur. Acad. Dermatol. Venereol. 10.1111/jdv.20062 (2024). [DOI] [PubMed]
  • 22.Jimenez, J. I., Jahankhani, H. & Kendzierskyj, S. Health care in the cyberspace: medical cyber-physical system and digital twin challenges. In Digital Twin Technologies andSmart Cities. Internet of Things (eds Farsi, M., Daneshkhah, A., Hosseinian-Far, A. & Jahankhani, H.) 10.1007/978-3-030-18732-3_6(Springer, Cham, 2020).
  • 23.Glines, K. R., Haidari, W., Ramani, L., Akkurt, Z. M. & Feldman, S. R. Digital future of dermatology. Dermatol. Online J.26, 1–15 (2020). 10.5070/D32610050455 [DOI] [PubMed] [Google Scholar]
  • 24.Jeong, H. K., Park, C., Henao, R. & Kheterpal, M. Deep learning in dermatology: a systematic review of current approaches, outcomes, and limitations. JID Innov.3, 100150 (2023). 10.1016/j.xjidi.2022.100150 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Phan, D. T. et al. A smart LED therapy device with an automatic facial acne vulgaris diagnosis based on deep learning and internet of things application. Comput. Biol. Med.136, 104610 (2021). 10.1016/j.compbiomed.2021.104610 [DOI] [PubMed] [Google Scholar]
  • 26.Yousef H., Alhajj M. & Sharma S. Anatomy, Skin (Integument), Epidermis. [Updated 2022 Nov 14]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470464/.
  • 27.Capon, F. The genetic basis of psoriasis. Int. J. Mol. Sci.18, 10.3390/ijms18122526 (2017). [DOI] [PMC free article] [PubMed]
  • 28.Bordukova, M., Makarov, N., Rodriguez-Esteban, R., Schmich, F. & Menden, M. P. Generative artificial intelligence empowers digital twins in drug discovery and clinical trials. Expert Opin. Drug Discov.19, 33–42 (2024). 10.1080/17460441.2023.2273839 [DOI] [PubMed] [Google Scholar]
  • 29.Subramanian, K. Digital twin for drug discovery and development—The virtual liver. J. Indian Inst. Sci.100, 653–662 (2020). 10.1007/s41745-020-00185-2 [DOI] [Google Scholar]
  • 30.Nct. Randomized Controlled Trial of Digital Twin Precision Treatment: a Novel Whole Body Digital Twin Enabled Precision Treatment for Type 2 Diabetes. https://clinicaltrials.gov/show/NCT05181449 (2021).
  • 31.Smith, A., Walsh, J. & Fisher, C. Using AI to create digital twins to accelerate Alzheimer’s disease clinical trials. J. Prev. Alzheimer’s Dis.6, S44 (2019). [Google Scholar]
  • 32.Zhao, S. et al. Smart identification of psoriasis by images using convolutional neural networks: a case study in China. J. Eur. Acad. Dermatol. Venereol.34, 518–524 (2020). 10.1111/jdv.15965 [DOI] [PubMed] [Google Scholar]
  • 33.Liopyris, K., Gregoriou, S., Dias, J. & Stratigos, A. J. Artificial intelligence in dermatology: challenges and perspectives. Dermatol. Ther.12, 2637–2651 (2022). 10.1007/s13555-022-00833-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Schaap, M. et al. Image‐based automated psoriasis area severity index scoring by convolutional neural networks. J. Eur. Acad. Dermatol. Venereol.36, 68–75 (2022). 10.1111/jdv.17711 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Youssef, K., Ullah, A., Rezai, P., Hasan, A. & Amirfazli, A. Recent advances in biosensors for real time monitoring of pH, temperature, and oxygen in chronic wounds. Mater. Today Bio22, 100764 (2023). 10.1016/j.mtbio.2023.100764 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Shetti, N. P. et al. Skin-patchable electrodes for biosensor applications: a review. ACS Biomater. Sci. Eng.6, 1823–1835 (2020). 10.1021/acsbiomaterials.9b01659 [DOI] [PubMed] [Google Scholar]
  • 37.Ahmad Tarar, A., Mohammad, U. & K. Srivastava, S. Wearable skin sensors and their challenges: a review of transdermal, optical, and mechanical sensors. Biosensors10, 56 (2020). 10.3390/bios10060056 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Park, H. et al. Integration of computer-simulated persons with multi-node thermoregulation model that considers the effect of clothing for skin surface temperature distribution analysis. Build. Environ.248, 111105, (2024). 10.1016/j.buildenv.2023.111105 [DOI] [Google Scholar]
  • 39.Atashipour, S. R. & Baqersad, J. Mechanical characterization of human skin—A non-invasive digital twin approach using vibration-response integrated with numerical methods. Med. Eng. Phys.121, 104058, (2023). 10.1016/j.medengphy.2023.104058 [DOI] [PubMed] [Google Scholar]
  • 40.Akbarialiabad, H. & Murrell, D. F. A new dawn for orphan diseases in dermatology: The transformative potential of digital twins. J. Eur. Acad. Dermatol. Venereol.10.1111/jdv.20062 (2024). [DOI] [PubMed]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemetary File (177.2KB, pdf)

Articles from NPJ Digital Medicine are provided here courtesy of Nature Publishing Group

RESOURCES